Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Safety and Efficacy of Insulin Aspart vs. Regular Human Insulin in Gestational Diabetes

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Novo Nordisk A/S
ClinicalTrials.gov Identifier:
NCT00065130
First received: July 17, 2003
Last updated: December 21, 2016
Last verified: December 2016

July 17, 2003
December 21, 2016
April 2000
December 2003   (Final data collection date for primary outcome measure)
Postprandial glycemic control
Not Provided
Complete list of historical versions of study NCT00065130 on ClinicalTrials.gov Archive Site
  • HbA1c (glycosylated haemoglobin A1c)
  • Postprandial endogenous insulin secretory response
  • Hypoglycemic episodes
  • Adverse events
Not Provided
Not Provided
Not Provided
 
Safety and Efficacy of Insulin Aspart vs. Regular Human Insulin in Gestational Diabetes
Safety and Efficacy of Insulin Aspart vs. Regular Human Insulin in Basal/Bolus Therapy for Patients With Gestational Diabetes
This trial is conducted in the United States of America (USA). The purpose of this study is to test whether NovoLog (insulin aspart) is a safe and at least as effective alternative to regular human insulin for the control of blood glucose after meals in women who develop diabetes during pregnancy.
Not Provided
Interventional
Phase 3
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
  • Diabetes
  • Gestational Diabetes
  • Drug: human insulin
  • Drug: insulin NPH
  • Drug: insulin aspart
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
27
December 2003
December 2003   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Subjects older than 35 years old will be considered
  • Gestational diabetes mellitus
Sexes Eligible for Study: Female
18 Years and older   (Adult, Senior)
Yes
Contact information is only displayed when the study is recruiting subjects
United States
 
 
NCT00065130
ANA-2067
No
Not Provided
Not Provided
Not Provided
Novo Nordisk A/S
Novo Nordisk A/S
Not Provided
Study Director: Global Clinical Registry (GCR, 1452) Novo Nordisk A/S
Novo Nordisk A/S
December 2016

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP